Madrigal Pharma Shares Double After Successful Phase II Results For Fatty Liver Drug

Competition is tough for a drug to cure fatty liver disease. After today ' s 150% jump, is Madrigal Pharmaceuticals the next darling of the biotech sector?

Source: Forbes.com Healthcare News - May 31, 2018 Category: Pharmaceuticals Authors: Karl Kaufman, Contributor Tags: NASDAQ:MDGL NASDAQ:GILD NYSE:AGN NASDAQ:VKTX NASDAQ:ICPT Source Type: news